title: Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality.
abstract: Although the antiplatelet agent clopidogrel is associated with an increased incidence of thrombotic thrombocytopenic purpura (TTP), available evidence is not sufficient to establish or disprove a causal relationship. We review and assess the evidence and case reports linking clopidogrel use with TTP and discuss how to approach the risk of TTP in patients taking clopidogrel.
authors.affiliation: Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: Navneet S
authors.initials: NS
authors.lastname: Majhail
authors.forename: Alan E
authors.initials: AE
authors.lastname: Lichtin
mesh_terms: D015984:Causality; D000077144:Clopidogrel; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced*; D018570:Risk Assessment; D013988:Ticlopidine / Q000009:adverse effects* / Q000031:analogs & derivatives
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine